Avtor/Urednik		Vrečer, M; Turk, S; Drinovec, J; Mrhar, A
Naslov		Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: meta-analysis of randomized trials
Tip		članek
Vir		Int J Clin Pharmacol Ther
Vol. in št.		Letnik 41, št. 12
Leto izdaje		2003
Obseg		str. 567-77
Jezik		eng
Abstrakt		Objective: To estimate the relative risk reduction of the clinical outcomes (coronary events, strokes, cardiovascular, non-cardiovascular and all-cause mortality) associated with statin therapy in primary and secondary prevention. Data sources: A literature search of the Medline and Cohrane databases for articles published from 1985 to July 2002 was performed. The data on systematic reviews and preliminary reports were also included in this study. Primary and secondary prevention trials and regression trials were eligible. Data extraction and statistical method: Data were extracted by 2 authors according to the defined inclusion criteria. Disagreements were resolved by consensus or by a third reviewer. Testing for heterogeneity was applied and on the basis of these results a fixed effect model or a random effect model was used for calculation of relative risk values (RR) and 95% confidence intervals (95% CI). Sensitivity analysis tested the impact of the individual study ‐ duration of study, type of statin therapy and study size. The number of patients needed to treat was calculated as an absolute measure of clinical effectiveness of statin therapy when appropriate. Results: Data from 15 trials with 63,410 participants and mean duration of treatment of 3.6 years, were included in this overview. Tests for heterogeneity showed that the variability between study estimates is sufficiently small to assume that they are estimating the same underlying treatment effect. Statin therapy was associated with a 22% reduction in total cholesterol, 29% reduction in LDL cholesterol, 12% reduction in triglycerides and 6% increase in HDL cholesterol. Overall (primary and secondary studies) statin therapy significantly reduces relative risk of coronary events (RR, 0.73, 95% CI, 0.68, 0.77, *p < 0.0001), relative risk of cardiovascular disease mortality (RR, 0.78, 95% CI, 0.73, 0.84, *p < 0.0001), relative risk of non-fatal (Abstract truncated at 2000 characters).
Deskriptorji		CORONARY DISEASE HYDROXYMETHYLGLUTARYL COA REDUCTASES MIDDLE AGE AGED SEX FACTORS HYPERCHOLESTEROLEMIA TREATMENT OUTCOME RANDOMIZED CONTROLLED TRIALS REPRODUCIBILITY OF RESULTS